|
Mutation Information
|
Mutation Site
|
T215F |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
zidovudine (AZT);tenofovir (TDF) |
|
Country
|
Cameroon |
Literature Information
|
PubMed PMID
|
30871487
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
BMC infectious diseases |
|
Title
|
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. |
|
Author
|
Takou D,Fokam J,Teto G,Santoro MM,Ceccherini-Silberstein F,Nanfack AJ,Sosso SM,Dambaya B,Salpini R,Billong SC,Gori C,Fokunang CN,Cappelli G,Colizzi V,Perno CF,Ndjolo A |
|
Evidence
|
Thymidine-analogue mutations (TAMs)-1 [T215FY (46.53%), M41 L (22.77%), L210 W (8.91%)], with cross-resistance to AZT and TDF, were higher compared to TAMs-2 [D67N (21.78%), K70R (19.80%), K219QE (18.81%)].
|
|
|
HIV Mutation Detail Information